SOURCE: Peregrine Pharmaceuticals Inc.

May 10, 2005 08:00 ET

CEO of Peregrine Pharmaceuticals, Inc. Interviewed by ExecutivesCorner

SAN DIEGO, CA -- (MARKET WIRE) -- May 10, 2005 -- ExecutivesCorner has published an in-depth interview with Steve King, President and CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), in which he talks at length about Peregrine’s current drug pipeline and recent successes with their star drug, Tarvacin™.

The entire PDF interview is available free online at www.ExecutivesCorner.com/documents/pdf/PPHM/PPHM_interview.pdf.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a broad portfolio of products under development directed towards the treatment of cancer, viruses and other diseases. Their oncology programs are primarily focused on the areas of anti-phospholipid technology, anti-angiogenesis and vascular targeting. They are also investigating potential antiviral applications for their antiphospholipid technology platform through collaborations with UT Southwestern and the National Institute for Allergy and Infectious Disease (NIAID), which is part of the National Institutes of Health.

When commenting on Peregrine’s broad technology platforms, Mr. King stated, “Our four platform technologies have broad applications in various therapeutic areas including cancer, virology and a number of other angiogenesis dependant diseases.” Mr. King also comments on the recent findings for Tarvacin™, claiming, “Our collaboration at the University of Texas Southwestern Medical Center of Dallas discovered that the target for Tarvacin™ becomes exposed on virally infected cells and viral particles of enveloped viruses.” Mr. King is excited about this development and looks forward to being able to initiate clinical trials in the near future.

Safe harbor for Forward-Looking Statements:

This press release may contain projection and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which Peregrine Pharmaceuticals has little or no control.

ExecutivesCorner does not endorse the views of any interviewees nor does it make stock recommendations. ExecutivesCorner has received no compensation for preparation and publication of this interview. For more information please visit www.ExecutivesCorner.com/disclaimer.aspx.

Contact Information